Global Information
회사소개 | 문의 | 비교리스트

세계의 신종 코로나바이러스(COVID-19) 파트너링 : 12개월의 서브스크립션

Global COVID-19 Partnering - 12 month subscription

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행정보 24 회/년 상품 코드 939909
페이지 정보 영문 120+ Pages
가격
US $ 2,495 ₩ 2,934,000 PDF by E-mail (Single User License)
US $ 3,995 ₩ 4,699,000 PDF by E-mail (Multi User License - 2 to 5 Users)
US $ 7,995 ₩ 9,404,000 PDF by E-mail (Single Site License - 6+ Users)
US $ 12,995 ₩ 15,286,000 PDF by E-mail (Global License)


세계의 신종 코로나바이러스(COVID-19) 파트너링 : 12개월의 서브스크립션 Global COVID-19 Partnering - 12 month subscription
발행정보 : 24 회/년 페이지 정보 : 영문 120+ Pages

세계의 신종 코로나바이러스(COVID-19) 관련 시장에서 제휴 계약의 동향과 조건에 대해 조사분석했으며, 최근 동향, 대표적인 거래의 개요, 활발한 사업자, 제휴 계약 디렉토리, 주요 거래(금액별) 등에 관한 정보를 정리하여 전해드립니다.

목차

개요

제1장 신종 코로나바이러스(COVID-19) 파트너링의 동향

  • 장기간 제휴
  • 가장 활발한 기업별
  • 거래 유형별
  • 산업 부문별
  • 개발 단계별
  • 기술 유형별

제2장 가장 활발한 거래 상대

제3장 최신 거래

제4장 제휴 거래 디렉토리

  • 회사 AZ별 제휴 거래
  • 거래치별 거래의 제휴
  • 업계별 제휴 거래
  • 거래 유형별 거래의 제휴
  • 개발 단계별 거래의 제휴
  • 테크놀러지 유형별 제휴 거래

제5장 파트너 계약 : 계약 문서

  • 거래 유형의 정의
  • Wildwood Ventures 소개
  • 현재의 제휴
  • 현재의 계약
  • CurrentPartnering로부터의 최근 리포트 타이틀
KSA 20.06.17

The Global COVID-19 Partnering report provides comprehensive understanding and unprecedented access to the COVID-19 partnering deals and agreements entered into by the worlds leading healthcare companies

12 month subscription of report updates

Updated twice monthly and delivered by email

Global COVID-19 Partnering report provides the full collection of COVID-19 disease deals signed between the world's pharmaceutical and biotechnology companies since the start of 2020.

This fast moving dealmaking report is updated twice monthly and sent to you by email over the 12 month subscription.

Trends in COVID-19 partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

COVID-19 partnering agreement structure

COVID-19 partnering contract documents

Top COVID-19 deals by value

Most active COVID-19 dealmakers

The report takes readers through the comprehensive COVID-19 disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering COVID-19 deals.

The report presents financial deal terms values for COVID-19 deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of COVID-19 dealmaking trends.

Chapter 1 provides an overview of the trends in COVID-19 dealmaking covering trends by most active companies, industry sector, deal type, stage of development, and technology type.

Chapter 2 includes the top 25 most active COVID-19 dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 includes an briefing on the latest COVID-19 deals announced in the past month.

Chapter 4 provides a comprehensive listing of all COVID-19 partnering deals signed and announced since the start of 2020. The chapter is organized by company A-Z, deal headline value, industry sector, deal type (collaborative R&D, co-promotion, licensing etc), stage of development at signing, and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 5 provides access to COVID-19 deals where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in COVID-19 partnering and dealmaking.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of COVID-19 technologies and products.

Report scope

Global COVID-19 Partnering report is intended to provide the reader with an in-depth understanding and access to COVID-19 trends and structure of deals entered into by leading companies worldwide.

Global COVID-19 Partneringreport includes:

  • Trends in COVID-19 dealmaking in the biopharma industry
  • Analysis of COVID-19 deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to COVID-19 deal contract documents
  • Comprehensive access to COVID-19 deal records
  • The leading COVID-19 deals by value
  • Most active COVID-19 dealmakers

The report includes deals for the following indications:

  • Viral: Coronavirus COVID-19

In Global COVID-19 Partnering, available deals and contracts are listed by:

  • Headline value
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global COVID-19 Partnering report provides comprehensive access to available deals and contract documents for COVID-19 deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise COVID-19 rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global COVID-19 Partnering report provides the reader with the following key benefits:

  • In-depth understanding of COVID-19 deal trends
  • Access COVID-19 deal headline, upfront, milestone and royalty data
  • Research actual contracts between COVID-19 partner companies
  • Comprehensive access to links to actual COVID-19 deals entered into by the world's biopharma companies
  • Indepth review of COVID-19 deals entered into by the top 10 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner COVID-19 opportunities
  • Uncover companies actively partnering COVID-19 opportunities

Table of Contents

Executive Summary

Chapter 1 - COVID-19 partnering trends in numbers

  • COVID-19 partnering over the years
  • COVID-19 partnering by most active company
  • COVID-19 partnering by deal type
  • COVID-19 partnering by industry sector
  • COVID-19 partnering by stage of development
  • COVID-19 partnering by technology type

Chapter 2 - COVID-19 most active dealmakers

Chapter 3 - COVID-19 recent deals

Chapter 4 - COVID-19 partnering deals directory

  • Partnering deals by company A-Z
  • Partnering deals by deal value
  • Partnering deals by industry sector
  • Partnering deals by deal type
  • Partnering deals by stage of development
  • Partnering deals by technology type

Chapter 5 - Partnering deals with a contract document

  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: COVID-19 partnering frequency by year
  • Figure 2: COVID-19 partnering most active
  • Figure 3: COVID-19 partnering by industry sector
  • Figure 4: COVID-19 partnering by deal type
  • Figure 5: COVID-19 partnering technology area
  • Figure 6: COVID-19 partnering stage of development
Back to Top
전화 문의
F A Q